Characteristics of study participants
| Participant group . | Age, y . | CD4 count (cells/μL) . | CD4 percentage . | CD8 count (cells/μL) . | CD8 percentage . | CD4:CD8 ratio . | HIV RNA level (copies/mL) . | Patients with viral load < 50 copies/mL . |
|---|---|---|---|---|---|---|---|---|
| HIV− controls (n = 16) | 39 (23-57) | 643 (410-1 053) | 44 (30-61) | 338 (150-753) | 22 (11-41) | 2.10 (0.85-4.27) | — | — |
| HIV+/HAART (n = 15) | 44 (27-59) | 609 (102-1 198) | 23 (12-48) | 1091 (254-3 749) | 42 (35-72) | 0.54 (0.19-1.37) | < 50 (< 50-46 775) | 10 of 15 (67%) |
| HIV+/IL-2+ HAART (n = 16)* | 44 (32-59) | 847 (488-1 253) | 39 (26-49) | 976 (504-1 754) | 43 (34-56) | 0.84 (0.55-1.35) | < 50 (< 50-30 024) | 9 of 16 (56%) |
| Participant group . | Age, y . | CD4 count (cells/μL) . | CD4 percentage . | CD8 count (cells/μL) . | CD8 percentage . | CD4:CD8 ratio . | HIV RNA level (copies/mL) . | Patients with viral load < 50 copies/mL . |
|---|---|---|---|---|---|---|---|---|
| HIV− controls (n = 16) | 39 (23-57) | 643 (410-1 053) | 44 (30-61) | 338 (150-753) | 22 (11-41) | 2.10 (0.85-4.27) | — | — |
| HIV+/HAART (n = 15) | 44 (27-59) | 609 (102-1 198) | 23 (12-48) | 1091 (254-3 749) | 42 (35-72) | 0.54 (0.19-1.37) | < 50 (< 50-46 775) | 10 of 15 (67%) |
| HIV+/IL-2+ HAART (n = 16)* | 44 (32-59) | 847 (488-1 253) | 39 (26-49) | 976 (504-1 754) | 43 (34-56) | 0.84 (0.55-1.35) | < 50 (< 50-30 024) | 9 of 16 (56%) |
Values are median (range).
Median time from last IL-2 cycle, 13 months (range 3-54); time from first IL-2 cycle, 3-8 years; and median total number of IL-2 cycles, 11 (range, 5-23).